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1. Introduction 
There is growing prevalence of cardiovascular diseases (CVD) and diabetes mellitus type 2 
(DM2) in the child and youth population, and particularly in young adults, secondary to an 
increase in their risk factors, which present themselves at very early stages of life. Among 
these, the most prevalent is obesity, which may increase rates of dyslipidemia, arterial 
hypertension (AH) and carbohydrate metabolism disorders, which are also recognized risk 
factors for cardiometabolic diseases (CMD). 
High prevalence of obesity has also been found in the pediatric population worldwide. An 
epidemiological study conducted in Feira de Santana, a city in the northeast of Brazil, 
including children from 5 to 9 years old showed rates of 9.1% and 4.4% for overweight and 
obesity respectively, confirming the finding of obesity at early stages of life. 
The literature has pointed out to the relationship between obesity in youth and premature 
death due to endogenous causes of cardiac/metabolic origin. It is therefore fundamental to 
know how and when the risk factors for CMD begin to affect vascular function and 
structure, and particularly, how to detect them early in order to enable the development of 
truly primary preventive strategies. This would make it possible to change the 
epidemiology of these chronic diseases, with consequent reduction in psychosocial and 
economic cost to the population and Health System, which is especially important in factor 
in developing countries. 
2. Impact of obesity on cardiometabolic risk factors in youth 
Obesity (defined as body mass Index [BMI] > 95th percentile, or BMI score z > 2.0) is a well 
defined and very complex disease of which overweight is merely one of the signs. 
Increasing obesity prevalence in youth over the last three decades has led to growing 
evidence of its implications for human health. Based on longitudinal studies, overweight has 
been shown to be an important risk factor for the development of atherosclerotic CVD, 
carbohydrate metabolism disorders, obstructive sleep apnea, cancers, intellectual 
deterioration, among others, therefore presenting elevated cumulative morbid-mortality. 
A follow-up study of American indigenous children over a mean period of 23.9 years, 
demonstrated that factors such as obesity, particularly the abdominal type (defined as waist 
circumference [WC] > 75th percentile), diminished glucose tolerance, and childhood AH are 
involved in the development of premature death and DM. In addition to obesity being the 
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earliest event in this chain of morbidity, the deregulation of glycemic homeostasis is 
probably the most important mediator between overweight and death. 
Nevertheless, a significant proportion of obese individuals may attain longevity without the 
previously mentioned comorbidities. This is due to the fact that the determinant of 
individual metabolic risk associated with accumulation of adipose tissue (AT) is not 
represented by its excess only, but above all, by its distribution, which can be determined by 
means of simple and available techniques such as WC measurement, as previously 
mentioned. 
AT is recognized as the largest energy store of free fatty acids (FFA) and triglycerides (TG), 
and more recently as an endocrine organ that regulates the secretion of adipokines, which 
coordinate energy metabolism, insulin sensitivity and feeding behavior, not only in adults 
but also in pediatric populations. Imbalance between visceral and subcutaneous AT is 
capable of altering its physiology.  In obese individuals, especially those with abdominal 
obesity, there is an increase of cytokines, such as interleukins (IL), tumor necrosis factor-
alpha (TNF-α), c-reactive protein (CRP), plasminogen activator inhibitor (PAI-1) and 
fibrinogen among others, known for their proinflammatory, prothrombotic and 
proatherogenic actions, and a decrease in a cytokine with opposite characteristics, called 
adiponectin. In addition, the adipocytes that constitute visceral AT present intense lipolytic 
activity and when in excess, promote an increase of FFA circulanting levels that contribute 
to the presence of ectopic fat deposition. 
These two basic mechanisms (imbalance in cytokine production and increase in FFA) favor 
both fat deposition in non habitual sites essential to the maintenance of glucose homeostasis, 
such as pancreas, liver and muscle, among others. This may lead to the development of 
insulin resistance (IR) and states of chronic inflammation with significant impact on 
carbohydrate metabolism and vascular system, promoting endothelial dysfunction. The 
inflammatory state is recognized by the increase in some cytokines (CRP, IL-6, TNF-α, etc) 
and is a great predictor of CVD. Therefore, it is rational to include CRP, especially high-
sensitivity CRP (hs-CRP), in screening for the risk of CVD, also in the pediatric population 
at risk of these diseases. 
Fatty liver deposition or hepatic steatosis (HS) is considered a hepatic component of the 
metabolic syndrome (MS) by the International Diabetes Federation (IDF), and in adult 
population it is an established predictor of dysglycemia and DM2. In youth, an association 
between obesity, particularly abdominal obesity and HS has been confirmed. Furthermore, 
the degree of steatosis in the liver has a decisive influence on the development of alterations 
in glycidic metabolism, with an important increase in hepatic glucose production, due to 
increase in gluconeogenesis. 
It is thus imperative to conduct studies on ectopic fat deposits in youths with excessive 
weight in order to diagnose individuals with this alteration and calculate a risk score for 
CVD and DM. This screening may be done by means of simple techniques such as hepatic 
enzyme measurements (aspartate aminotransferase [AST], alanine aminotransferase [ALT] 
and hepatic ultrasound and/or sophisticated techniques (not always available in developing 
countries) such as nuclear magnetic resonance (NMR) with spectroscopy or hepatic biopsy, 
which is an invasive method, especially for children. Research in intramyocellular fat using 
NMR is also fundamental for determining peripheral muscle insulin sensitivity however the 
technique is not available for clinical use. 
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2.1 Cardiovascular system 
Cardiovascular screening is normally recommended for adults, especially those with a 
family history positive for CVD. Nevertheless the combination of atherogenic diet, 
sedentary lifestyle and genetic have resulted in overweight and atherogenic dyslipidemia 
(decrease in high-density-lipoprotein cholesterol [HDL-C], increase in low-density-
lipoprotein cholesterol [LDL-C] and TG at very early stages of life, thus anticipating the 
need for screening the cardiovascular system. 
Although the vascular pathology in children with obesity and DM has been described, the 
course of development of these abnormalities has not yet been fully explained. In adults, 
abnormalities in vascular function precede the development of the anatomic or structural 
pathology. Vascular dysfunction, including reduction in endothelial function and vascular 
complacency and increase in inflammatory markers are therefore the initial findings in 
subjects with obesity, dyslipidemia, AH and carbohydrate metabolism disorders. 
Inflammation and maintenance of these risk factors subsequently lead to the development of 
atherosclerosis with alteration in vascular structure and increase in its rigidity. 
2.2 Mechanism of atherogenesis 
When elevated, LDL-C infiltrates the arterial endothelium, producing fat striae, even at very 
early ages in life (1st and 2nd decades) and if dyslipidemia persists, various subtypes of 
white globules, similar in shape, infiltrate the vascular wall and secrete inflammatory 
cytokines and oxidative molecules, with development of an inflammatory state and 
oxidative stress (OS). 
OS, defined as imbalance between the concentrations of reactive oxygen species (ROS), such 
as superoxide and antioxidants (superoxide dismutase and catalase, among others), are 
essential for the development of endothelial damage, representing the initial and 
fundamental stage that is interposed between the formation of atherosclerotic plaque and 
the thrombus. Signaling pathways that regulate cytokine expression, such as the nuclear 
factor kappa B transcriptional pathway (NF-kB), is also activated by OS, resulting in the 
induction of adhesion molecule expression and inflammation on the vascular wall, 
contributing to the atherogenic process. In association, the clotting cascade and platelet 
aggregation are activated in an effort to repair the atheromatous lesion. This process can 
induce occlusive thrombi, infarctions and generalized micro and macro-vascular disease. 
Some systemic markers that represent OS have been identified in youngsters, confirming 
early onset of the atherosclerotic process. 
In various studies, including our study in adolescents, inflammation markers, such as the 
simple overall leukocyte count and high-sensitivity CRP (hs-CRP) have been shown to be 
elevated in this group with clear demonstration of the relationship between inflammation 
and obesity, MS and a number of its components. The clinical usefulness of monitoring 
these markers in the pediatric population has not been well studied, nevertheless, some 
authors recommend that it should be measured, based on the hypothesis that the subclinical 
inflammation present in MS results from a silent and progressive atherosclerotic process 
that started in the first decade of life that could be stopped or at least delayed if identified. 
In addition, thrombosis markers, such as fibrinogen, IL (6,8, 1 B), TNF-α, monocyte 
chemotactic protein-1 (MCP-1) and PAI-1 have elevated levels in  obese youngsters with MS. 
Up until very recently, only necropsy studies warned about the beginning of atherogenesis 
early in life, and non invasive techniques have attested to this sequence of events. 
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Ultrasound of the neonatal and fetal aorta have indicated that retardation of fetal growth, in 
utero exposure to hypercholesterolemia and maternal smoking habits, in addition to diabetic 
macrossomia may also contribute as risk factors for CVD. 
Endothelial function may be investigated invasively or non-invasively by means of various 
techniques, in several vascular sites and by diverse pharmacological or mechanical stimuli. 
The non invasive technique most frequently used clinically, involves capturing images by 
high resolution ultrasound after stimulation determined by ischemia induced by brachial 
artery occlusion (reactive hyperemia test). A similar non invasive ultrasound technique is 
used to evaluate the vascular structure by measuring the thickness of the intima media layer 
of the common carotid (IMCC). Larger IMCC thickness has been observed in youngsters 
with traditional risk factors for CMD, such as obesity, dyslipidemia and hypertension. 
Another study of our group was conducted in 128 adolescents (age 14.6 ± 2.7 years, BMI z 
score 1.9 ± 0.8).  The IMCC thickness was measured and the reactive hyperemia test 
performed. We found a statistically significant positive correlation between BMI and 
reactive hyperemia test. Levels of soluble intercellular adhesion molecule (sICAM-1), 
soluble vascular cell adhesion molecule (sVCAM-1) and PAI-1 was also measured and the it 
was found positive association between abdominal obesity and sVCAM-1 and also with 
adiposopathy (defined as the presence of three or more adipocitokines such as IL-6, FNT-α, 
CRP, leptin and high molecular weight adiponectin) and sICAM-1 confirming the 
hypotheses of early onset of the atherosclerotic process. 
Although atherosclerosis is clinically manifested in adult life, it is clear that a long and 
asymptomatic phase precedes its development. Apparently it begins in childhood and there 
are evidences in populations of developed and developing countries that the proinflammatory 
state and OS are triggers for atherogenesis. Therefore, in order to be effective, primary 
prevention of CVD must occur in this age group, especially in those with excessive weight. 
Even more important is the fact that the major determinant of both inflammation and OS is 
abdominal obesity, which constitutes a risk factor believed to be modifiable, therefore, 
intervention is recommended, and with adequate control its consequences are reversible. 
2.3 Insulin resistance and carbohydrate metabolism disorders 
Insulin plays a vital role in glucose metabolism and energy homeostasis. Its action depends 
on two basic factors: pancreatic secretion and tissue sensitivity. Peripheral insulin sensitivity 
is responsible for glucose uptake (by the muscle) and for suppression of glucose production 
(by the liver). 
IR occurs when a defined quantity of insulin produces a subnormal biologic response, more 
specifically, it is characterized by reduction in the ability of insulin to stimulate the use and 
uptake of glucose by peripheral tissues and suppress hepatic glyconeogenesis. As an 
anabolic and mitogenic hormone, insulin acts on stimulating the synthesis of glycogen, FFA, 
TG and proteins and also in reducing proteolysis and lipolysis. 
One of the major consequences of obesity is IR, and is almost a consensus that it represents 
the link between some cardiovascular and metabolic risk factors in both, adults and 
youngsters. There is also association between this state and the polycystic ovary syndrome, 
nonalcoholic fatty liver disease, obstructive sleep apnea and some specific types of cancer. 
Fasting insulinemia is not a good marker for IR diagnosis, due to the lack of standardization 
among the tests and non definition of normal values, particularly for youngsters. The gold 
standard method for the diagnosis of insulin sensitivity in adults as well as children and 
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youngsters is the hyperinsulinemic-euglycemic clamp, however it is difficult to use 
clinically. One simple and validated index is the homeostasis model f insulin resistance 
(HOMA-IR) ([fasting insulin (U/mL)] x [fasting glycemia (mg/dL)]/405). Nevertheless, 
there is no consensus about the cut-off point for the pediatric population. Keskin and 
collaborators, after a study with adolescents proposed the value > 3.16. 
Glycemia per se is an important risk factor for adverse cardiovascular events, and its control 
leads to cardioprotection, particularly when early intervention is provided. Several studies 
with strict glycemic control, such as The Diabetes Control and Complications Trial (DCCT) , 
The Epidemiology of Diabetes Interventions and Complications Study (EDIC) among others 
confirmed this hypothesis. Various mechanisms have been proposed to explain this 
relationship: 1. Protein glycation: this process leads to the production of advanced glycation 
end products (AGE) which, after activation of their receptor (RAGE) in endothelial cells, 
smooth muscle cells and macrophages, determine both increase in the activation of 
transcription factors in the vessel that favor atheroma plaque formation, increase in 
adhesion molecule expression and cytokine secretion; 2. Circulating lipoprotein glycation: 
potentiates the atherogenicity of LDL-C, thus contributing to atherogenesis; and 3. Direct 
effect glucose on the vascular wall: contributes to endothelial dysfunction by increasing 
adhesion molecule expression, reducing plasminogen activator production and increasing 
PAI-1 production, generating a hypofibrinolytic and inflammatory state 
3. Metabolic syndrome 
3.1 Epidemiology 
Since 1970, in the United States, the prevalence of overweight among children from 2 to 5 years 
of age has doubled, and among children and adolescents from 6 to 19 years of age, tripled. At 
present 17% of the pediatric population is overweight. In Brazil the panorama is no different, 
with growing rates ranging between 4.4% and 33.6%, depending on the methodology used for 
defining obesity and the characteristic of the sample studied. It is always important to 
remember that biological, social, cultural and economical factors are involved in the 
development of obesity and Brazil is a country with heterogeneous characteristics in terms of 
these factors. The  Brazilian Institute of Geography and Statistic in 2012 showed rate of 10% of 
overweight and 7.3% of obesity among children and adolescents. An epidemiologic study 
conducted with 699 children in Feira de Santana, BA, has confirmed this fact by finding 
prevalence of 8.6%, 9.1% and 4.4% of underweight, overweight and obese children, 
respectively as already mentioned. 
In this same population blood pressure levels were analyzed and even at a mean age of 7.1 
years, 3.6% of the sample presented elevated arterial pressure, with an odds ratio of 4.4 and 
13.0 higher for those who were overweight and obese respectively. 
Data obtained from the four largest regions in the world (United States of America, Latin 
America, Europe and Asia) reinforce the importance of MS in the pediatric population because 
it affects individuals of both sexes, in the major ethnic groups, but above all, those who are 
overweight. 
The estimated prevalence of MS among individuals aged 2 to 19 years is ~10% (1,2% to 
22,6%), from ~2% among children and adolescents with normal weight and ~32% among 
the obese, but with prevalence of up to 60% in this special group. Thus the odds of 
presenting MS is 15 times higher among overweight youngsters when compared with 
individuals of normal weight. The information with regard to sex is conflicting, but there is 
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a trend towards higher prevalence among men, because they have greater predisposition for 
abdominal obesity. Age is another factor that must be taken into consideration, and 
adolescents are affected to a larger extent than children. 
The National Health and Nutrition Examination Survey (NHANES) was the population 
study that analyzed ethnic differences, and it pointed out a higher rate of MS among 
Caucasians, and a lower rate among Afro-Americans. This fact is surprising, since the 
outcomes of MS (acute myocardial infarction and DM2) are more frequent among Afro- 
Americans, probably due to greater IR found among the youngsters in this ethnic group. 
Nevertheless, this IR is initially compensated by increased insulin secretion and clearance, 
consequently with less risk of MS. As the increased insulin secretion probably precedes the 
state of IR, this high level of insulin, plays a fundamental role in the physiopathology of the 
syndrome. Hyperinsulinemia and IR are linked to endothelial dysfunction (ED) in adults, a 
relationship between HOMA-IR and IMCC thickness. 
In Brazil the prevalence of MS among youngsters is very similar to that in developed 
countries, particularly among the obese. A study conducted with 548 school children in Feira 
de Santana, BA, with a mean age of 11.1 years, showed a prevalence of 31.3% among those 
who were overweight (BMI z score > 1.5). Abdominal obesity was the most frequent 
traditional component of MS found in the total sample (68.3%) confirming the fundamental 
role of visceral AT accumulation in development of the syndrome. This was followed by 
hypertriglyceridemia (29.3%), reduction in HDL-C (28.4%) and elevation of arterial blood 
pressure (17.4%). Interestingly, no alteration in carbohydrate metabolism was detected, in spite 
of the oral glucose tolerance test having been performed for diagnosis of carbohydrate 
metabolism disorders. Another study, also conducted in the Brazilian northwest confirmed the 
association between overweight and diagnosis of the syndrome, with rates of 22.6% and 59.3% 
in the total sample and in the obese subgroup, respectively. An analysis of 99 adolescents in 
the southeast of Brazil demonstrated a lower prevalence of the syndrome (6%) and also no 
cases of it were observed among those with normal weight and overweight (BMI z score > 1.5 
and < 2.0). Nevertheless, among the obese (BMI z score > 2.0), the rate increases to 26.1% and 
once again, no cases of carbohydrate metabolism disorders were detected. Thus, the Brazilian 
data with regard to the component "glucose metabolism disturbance" of MS, diverge from 
those in the literature, particularly the North American data, which point towards and increase 
in the rates of pre-diabetes and DM2 in the obese pediatric population. The possible causes of 
this divergence, apart from the non uniformity of diagnostic criteria for the syndrome, would 
be the lower severity of obesity in the Brazilian population, which is a recognized factor for the 
development of alteration in glycid metabolism, in addition to the probable presence of 
protective genetic and environmental factors. 
This epidemiologic profile indicates that obese youngsters must be considered at risk for 
cardiometabolic diseases and therefore considered targets for preventive and therapeutic 
strategies. However, in developing countries it has been suggested that screening for MS 
should also be done in normal weight individuals if the objective is prevention of CVD and 
DM2, because, in the same way as with obese individuals, this population may present 
disorders linked to metabolism and the cardiovascular system. 
3.2 Definition, diagnosis and clinical importance 
MS is defined as a constellation of specific anthropometric, physiological and biochemical 
abnormalities that predispose affected individuals to the development of CVD and DM2, 
described in adults in 1988 by Reavan and collaborators. 
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In youngsters the non existence of a universally accepted definition for the diagnosis of the 
syndrome is recognized, probably because of the dynamic aspects related to growth and 
development, and it is a real barrier. For example, individuals develop IR during puberty, 
and the normal levels of lipids and arterial blood pressure vary according to age and sex. 
Another complicating factor is the absence of standardization of the measurement of 
abdominal obesity, as well as its cut-off points. Thus, the criteria used for defining MS in the 
pediatric population are adaptations of criteria used for adults, and none of them are widely 
accepted. Nevertheless, the majority of them include the following elements: 1. Elevation of 
TG; 2. Reduction in HDL-C; 3. Increase in arterial blood pressure; 4. Alteration in plasma 
glucose; and, 5. Increase in abdominal obesity. 
Based on data from NHANES III (1988 - 1994), Cook and collaborators have suggested a 
definition adapted from the criteria defined by the National Cholesterol Education Program 
- Adult Treatment Panel III, NCEP/ATP-III), since Ferranti and collaborators, in spite of 
proposing definition also based on the NCEP/ATP-III criteria, used different cut-off points 
for each criteria. A study conducted at the School of Medicine of Yale University by Weiss 
and collaborators, used another criterion, replacing WC used in the previously described 
definitions, by the BMI, because they proved this index to be less subject to variations 
resulting from age and ethnic group (Table 1). 
 
Epidemiological and clinical aspects in developing country 
Criteria / 
components
Cook et al. de Ferranti et al. Weiss et al. 
Abdominal obesity WC1 > 90th percentile WC1 > 70th percentile z (BMI)6 > 2 
Glycid metabolism FG2 > 110 mg/dL 
FG2 > 110 mg/dL 
TG3 > 110 mg/dL 
Glycemia (OGTT7) of 
140 to 200 mg/dL 
Dyslipidemia 
TG3 > 110 mg/dL or
HDL4 > 40 mg/dL 
or 
HDL4 > 45 mg/dL 
(men) and < 
50mg/dL (women) 
TG3 > 95th percentile 
or 
HDL4 < 5th percentile 
Arterial hypertension BP5 > 90th percentile BP5 > 90th percentile BP5 > 95th percentile 
*WC = waist circumference; 2FG = fasting glycemia; 3TG = triglycerides; 4HDL-C = high density 
cholesterol; 6z BMI = z score of body mass index; 7 OGTT = oral glucose tolerance test; 8 BP = blood 
pressure. 
Source: Adapted from Pergher et al (2010). 
Table 1. Criteria for classification of the metabolic syndrome in children and adolescents, 
proposed by Cook et al., de Ferranti et al. and Weiss et al. in the presence of at least three of 
the five criteria 
The organizations, NCEP/ATP, World Health Organization and IDF have suggested criteria 
for the child and young population based on the criteria proposed for the adult population 
(Table 2). The new IDF definition is interesting as it divides the groups according to age: from 
10 to 16 years and over 16 years, children under the age of 10 years being excluded due to the 
non existence of data related to this age range. The authors also suggested that in children 
under the age 6 - 10 years the syndrome should not be diagnosed, but that the need for weight 
reduction must be emphasized in those with abdominal obesity. For children over the age of 
10 years, the syndrome is diagnosed by the presence of abdominal obesity, defined by the WC 
measurement, associated with two or more clinical criteria (hypertriglyceridemia, low levels of 
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HDL-C, AH and hyperglycemia). For the other factors, cut-off points were established by 
means of a fixed value, which in truth, is contrary to the other proposals for child and young 
populations. Nevertheless, the use of percentiles is also criticized, particularly in the transition 
to the adult stage, since the cut-off points for the criteria for this population are fixed and not 
based on percentiles. Thus, when an individual aged 18 years is analyzed using the fixed cut-
off points and those based on the percentile tables, there may be a difference in the diagnosis. 
As there is increasing prevalence of childhood obesity, as well as other risk factors for CVD 
and DM2, it has become necessary to conduct studies for standardizing criteria that are 
simple to apply for the diagnosis of MS in the child and young populations. Early diagnosis 
followed by treatment, which up to now has been directed towards individual components 
of the syndrome, particularly intervention in lifestyle, is fundamental for reducing the 
progression of MS rates in children and adolescents. 
Over the last decade questions have arisen about the real existence of the syndrome, 
especially in the child and young populations, in terms of whether the syndrome represents 
a distinct clinical entity, or only a constellation of factors linked to obesity, occurring in the 
same individual, since its diagnosis does not aggregate greater risk of cardiometabolic 
disease than its components evaluated individually (visceral obesity, dyslipidemia, AH, 
alteration in carbohydrate metabolism and IR). In a concrete manner, however, there are: 1. 
Alarming data on the prevalence of the syndrome and the relationship between its 
components and cardiometabolic complications at a very early age, with thickening of the 
IMCC layer and atherosclerotic lesions in the arterial network; 2. Information that confirms 
that the diagnosis of overweight and MS in childhood are predictors of MS and its 
consequences in the adult population; 3. Relationship between MS and DM2 in adult life 
and similar association in children and adolescents; 4. Association between this syndrome in 
childhood and other disorders, including hyperuricemia, HE, polycystic ovary syndrome 
and obstructive sleep apnea; and 5. That it has been accepted as a simple clinical instrument 
for the early detection of DM2 and ACVD and individuals at risk for these conditions. 
In addition to all these affirmations, the recognition of a probable physiopathological basis 
linked to visceral obesity/IR as a link between the components of MS, enables the clinician 
to have a broader vision of the risks of excess AT, even in very young individuals, thus 
changing his/her practical conduct, by systematic investigation of the factors that constitute 
the syndrome and its consequences. Thus, preventive and therapeutic measures are adopted 
earlier, thereby reducing the chance of development of cardiovascular outcomes. 
Nevertheless, it is worth emphasizing that there is no consensus about the benefits of 
diagnosing MS in the pediatric population, and future studies will probably be developed 
with the aim of establishing which individual component of MS creates the greatest future 
risk and should be the target for therapy. 
1. National Cholesterol Education Program - Adult Treatment Panel III: modified criteria 
for children and adolescents 
Definition of MS: presence of three or more of these conditions (A-B-C-D-E): 
 
A FG1 > 110 mg/ dL (6.1 mmol/L) or >100 mg/ dL (5.6 mmol/L) 
B WC2 > 90th percentile of sample distribution 
C TG3 > 110 mg/ dL (1.13 mmol/L) 
D HDL-C4 < 40 mg/ dL (1.04 mmol/L) 
E BP5 > 90th percentile of sample distribution 
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2. International Diabetes Federation (IDF) criteria for children and adolescents 
Definition of MS: presence of central obesity (A) in addition two or more of the conditions 
(B-C-D-E) 
Criteria according to age 
 
  
6 to <10 years of age
10 to 16 6 to <10 
16 years of age 
  years of age 
A WC2  > 90th percentile  
B TG3 
 > 150mg/ dL  
MS cannot be (1.7mmol/L)  
C HDL-C4 
diagnosed, < 40 mg/dL (1.03  
but future evaluation mmol/L)  
  must be made if Systolic BP5 >130 Use existing 
D BP5 
there is presence of mmHg or IDF criteria 
family history of MS, Diastolic BP5 > 85 for the adult 
  DM2, dyslipidemia, mmHg population 
 FG1 cardiovascular   
E 
or previous diagnosis 
of 
disease, 
hypertension and /
>100 mg/dL (5.6 
mmol/L) 
 
 diabetes mellitus or obesity.  
 type 2 (DM2)    
3. World Health Organization (WHO) criteria modified for children and adolescents 
Definition of the MS: presence of three of more of these conditions (A-B-C-D-E): 
 
A BMI6 > 95th percentile 
B Abnormal Glucose Homeostasis Hyperinsulinaemia or IFG7 or IGF8 
C BP5 > 952th percentile 
D TG3 
> 105/136 mg/dL (1.2/1.5 mmol/L) for children 
aged <10 years and > 10 years respectively 
E HDL-C4 < 35 mg/ dL (0.9 mmol/L) 
1FG = fasting glycemia 2WC = waist circumference; 3TG = triglycerides; 4HDL-C = high-
density cholesterol; 5BP = blood pressure, 6z BMI = z score of body mass index. 
Source: Adapted from Tailor et al. (2009). 
Table 2. Summary of the Metabolic Syndrome (MS) definitions used in the studies. 
4. Conclusions 
The prevalence of obesity among youngsters presents epidemic proportions with significant 
implications for cardiovascular and metabolic health at a very early age in life. There are 
increasing rates of MS in children and adolescents, which points towards the premature 
development of CVD and DM2 in the next generation of adults. IR, determined by 
abdominal obesity appears to represent the link between the components of MS in this age 
range, and functions as a predictor for CVD and disturbances in carbohydrate metabolism. 
Therefore, the WC measurement should be considered a screening instrument for the 
identification of youngsters with a cardiometabolic disease phenotype. 
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As a consequence of this abdominal obesity-IR binomial, a systemic inflammatory state is 
produced, which functions as a trigger for the atherogenic process. The earlier the onset of 
overweight, the more prematurely this will manifest clinically. Therefore, in order to 
implement primary prevention of CMD, investigation/prevention/treatment of risk factors, 
such as obesity, dyslipidemia, AH and disturbances in carbohydrate metabolism and its 
consequences must begin in the initial stages of life. 
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